MicroStrategy
MSTR
Adobe
ADBE
Salesforce
CRM
Apple
AAPL
Meritage Homes
MTH
US Stock MarketDetailed Quotes
BMEA Biomea Fusion
- 4.230
- +0.150+3.68%
Close Dec 20 16:00 ET
- 4.220
- -0.010-0.24%
Post 19:59 ET
153.29MMarket Cap-1.05P/E (TTM)
4.280High3.960Low858.97KVolume4.020Open4.080Pre Close3.56MTurnover3.83%Turnover RatioLossP/E (Static)36.24MShares20.21052wk High2.02P/B94.99MFloat Cap3.61052wk Low--Dividend TTM22.46MShs Float43.690Historical High--Div YieldTTM7.84%Amplitude2.840Historical Low4.138Avg Price1Lot Size
Trending US Stocks
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.
Biomea Fusion Stock Forum
Icovamenib met the primary endpoint, displaying a meaningful statistically significant placebo-corrected mean reduction in HbA1c in the prespecified per protocol patient population
Icovamenib was well-tolerated, with no adverse-event related discontinuations, no hypoglycemic events and no serious adverse events
Yet all the analysts are giving target price from a low 11$ to a 50/60 and above.
What's your take?
1. NFA
2. Do not open position without chart confirmation, indicators, momentum.
3. Check current shorts availability on FINTEL.io
4. Scale out and secure profits
5. Always remember shorts include dark pools.
6. Most importantly, don’t blame for your losses. I already give watchlist and stock education. The ball is on you.
$KULR Technology (KULR.US)$ PR 12/17: Signs Service Agreement to Launch KULR ONE Space Battery. COH $13.4M good for 9 months✅
$Wearable Devices (WLDS.US)$ PR 12/17:...
Biomea Fusion Inc - Icovamenib Meets Primary Endpoint With Significant Reduction in Hba1C
Biomea Fusion Announces Positive Topline Results from Ongoing Phase II COVALENT-111 Study in Patients with Type 2 Diabetes
Tuesday, 17th December at 8:10 am
• Icovamenib met the primary endpoint, displaying a meaningful statistically significant placebo-corrected mean reduction in HbA1c in the prespecified per protocol patient population
• Best response achieved in target, beta-cell deficient patients on one or more antidiabetic agents at baseline, showing a placeb...
No comment yet